Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NPCE | Common Stock | Sale | -$220K | -15.7K | -0.46% | $14.02 | 3.42M | May 1, 2024 | See Footnotes | F1, F2 |
transaction | NPCE | Common Stock | Sale | -$124K | -8.84K | -0.26% | $14.01 | 3.41M | May 2, 2024 | See Footnotes | F1, F2 |
transaction | NPCE | Common Stock | Sale | -$65.6K | -4.67K | -0.14% | $14.03 | 3.41M | May 3, 2024 | See Footnotes | F1, F2 |
Id | Content |
---|---|
F1 | These Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI. |
F2 | This report on Form 4 is jointly filed by OrbiMed Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. |